Quick Answer
SAB Biotherapeutics, Inc. reported Operating Income Loss of -$48.95 million for the year ending 2025.
- SAB Biotherapeutics, Inc. showed a decrease of -14.1% in Operating Income Loss from 2024 to 2025.
- This data is from SAB Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $813.9 thousand | Q2 2021: -$2.87 million | Q3 2021: -$3.99 million | Q1 2022: -$6.71 million | Q2 2022: -$6.54 million | Q3 2022: -$7.81 million | Q1 2023: -$7.40 million | Q2 2023: -$6.48 million | Q3 2023: -$5.32 million | Q1 2024: -$11.39 million | Q2 2024: -$10.20 million | Q3 2024: -$11.31 million | Q1 2025: -$10.77 million | Q2 2025: -$9.73 million | Q3 2025: -$12.68 million.
- Over the full 6 years of available data (2020 to 2025), SAB Biotherapeutics, Inc.'s Operating Income Loss has declined by 338.1%.
- Historical annual values: Fiscal year 2025: -$48.95 million | Fiscal year 2024: -$42.91 million | Fiscal year 2023: -$38.08 million | Fiscal year 2022: -$28.92 million | Fiscal year 2021: -$13.39 million | Fiscal year 2020: $20.56 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: